Rizatriptan Tablet, Film Coated
Product Images NDC 71335-1352

5 FDA label images from Bryant Ranch Prepack · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rizatriptan (NDC 71335-1352). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A line graph showing the estimated probability of response over hours post-dose for Rizatriptan Benzoate Tablets 5 mg, Rizatriptan Benzoate Tablets 10 mg, and a placebo. The x-axis represents time in hours post-dose from 0 to 2, and the y-axis shows the estimated probability of response in percentage from 0% to 100%. Both Rizatriptan doses show a higher probability of response compared to placebo over time.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A line graph showing the estimated probability of remediation or rescue over 24 hours post-dose. The graph compares three groups: Placebo, Rizatriptan Benzoate Tablets 5 mg, and Rizatriptan Benzoate Tablets 10 mg, with the probability increasing over time for each treatment group.*
FDA Label Image

Label Image (Lbl713351352)

Label Image (Lbl713351352)
Label for Rizatriptan Benzoate 10 mg tablet in blister packaging by Bryant Ranch Prepack. The label indicates it compares to Maxalt 10 mg tablet from Macleods Pharmaceuticals Ltd. The package contains 10 tablets with NDC 71335-1352. Storage instructions recommend room temperature 20°-25°C (68°-77°F). The label also includes a barcode and a caution to keep drugs out of children's reach.*
FDA Label Image

Fig-5 (Rizatriptan Fct Figure 5)

Fig-5 (Rizatriptan Fct Figure 5)
A line graph comparing the percent effect over hours post stage 2 dose between Rizatriptan Benzoate Orally Disintegrating Tablets and placebo. The x-axis represents hours post dose (0.5 to 2 hours), and the y-axis represents percent with 95% confidence intervals. Rizatriptan shows a higher percent effect compared to placebo over time.*
FDA Label Image

Rizatriptan-structure (Structure1)

Rizatriptan-structure (Structure1)
Chemical structure of rizatriptan, showing its key molecular components including the indole ring system and associated side chains, along with an adjacent benzoic acid moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.